Skip to main content
logo
Soleno Therapeutics, Inc. (SLNO)
May 18, 2026 - SLNO was delisted (reason: acquired by NBIX)
53.01
0.00 (0.00%)
Inactive · Last trade price on May 15, 2026

Soleno Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
96.0420.89-175.85-38.99-24.07-30.91
Depreciation & Amortization
2.032.021.991.961.961.96
Other Amortization
0.040.04----
Loss (Gain) From Sale of Investments
-2.76-3.52-4.9---
Stock-Based Compensation
47.2245.8599.965.952.533.28
Other Operating Activities
3.66.163.693.22-0.45-0.95
Change in Accounts Receivable
-47.14-28.21----
Change in Inventory
-15.86-14.03----
Change in Accounts Payable
3.983.615.671.37-1.48-0.24
Change in Other Net Operating Assets
18.3913.990.351.560.72-0.91
Operating Cash Flow
105.5346.8-69.1-24.94-20.78-27.77
Operating Cash Flow Growth
------
Capital Expenditures
-0.11-0.07-0.22--0.01-0.02
Investment in Securities
-186.63-201.71-225.46---
Investing Cash Flow
-186.74-201.78-225.68--0.01-0.02
Long-Term Debt Issued
--49.89---
Long-Term Debt Repaid
------0.01
Total Debt Repaid
------0.01
Net Debt Issued (Repaid)
--49.89---0.01
Issuance of Common Stock
234.88238.11163.14180.0214.11-
Repurchase of Common Stock
-100.89-100.89---0.02-0.12
Other Financing Activities
-1.09-0.06----
Financing Cash Flow
132.9137.16213.03180.0214.09-0.13
Net Cash Flow
51.7-17.82-81.75155.08-6.7-27.92
Free Cash Flow
105.4246.73-69.31-24.94-20.79-27.79
Free Cash Flow Growth
------
Free Cash Flow Margin
36.99%24.54%----
Free Cash Flow Per Share
1.950.89-1.73-1.51-2.48-5.23
Levered Free Cash Flow
91.6748.27-7.47-12.82-11.71-15.79
Unlevered Free Cash Flow
95.0151.66-7.33-12.82-11.71-15.79
Cash Interest Paid
4.884.530.21---
Cash Income Tax Paid
0.010.010.040.01--
Change in Working Capital
-40.64-24.636.022.93-0.76-1.15
SEC Filings: 10-K · 10-Q